
Blend · Pen
Glow Blend
$199A three-peptide blend for laboratory research into tissue repair, skin biology and connective-tissue signalling.

EternaGen / Research use onlyBlend · Research use only
A two-peptide blend used to explore how different signals influence the body’s growth-hormone system.
Available to approved purchasers
Can’t find the right record?Send support the product name or batch code.
Contact supportProduct information
A two-peptide blend used to explore how different signals influence the body’s growth-hormone system.
CJC-1295 and ipamorelin influence growth-hormone signalling through different pathways. Each has some early human research, but the combination, its long-term effects and meaningful health outcomes have not been established.
CJC-1295 is a long-acting analogue of growth-hormone-releasing hormone. Ipamorelin is a ghrelin-receptor agonist and growth-hormone secretagogue. Evidence for each molecule must be kept separate from evidence for the fixed blend.Specifications
Supplier-origin documentation will be published only after EternaGen verifies the source and record details.
Health Canada lists the named compound or components among unauthorized injectable drugs identified in the Canadian market. A research-use label does not make an unauthorized product suitable or legal for personal use.
Explore the research
Check what was studied, what researchers observed, and the limitation attached to each finding.
Short CJC-1295 studies in healthy adults measured pharmacokinetics and sustained changes in circulating growth hormone and IGF-I.
Evidence so far: Early human pharmacologyA phase 2 ipamorelin trial after bowel resection studied time to a standardized meal and found no significant difference on key or secondary efficacy analyses.
Evidence so far: Negative proof-of-concept trialThe individual studies do not test this CJC-1295 plus ipamorelin blend, its ratio, or long-term clinical outcomes.
Evidence so far: Combination evidence gapProposed mechanism
CJC-1295 and ipamorelin act through different receptors upstream of growth-hormone signalling. Measuring growth hormone or IGF-I shows pharmacodynamic activity; it does not by itself establish a meaningful health outcome.
Evidence gaps
Primary sources